Similar articles for PMID: 25188343

Year	Number of Results
1991	1
1993	2
1994	1
1995	2
1996	6
1997	2
1998	1
1999	2
2000	2
2001	2
2002	5
2003	2
2004	4
2005	11
2006	5
2007	3
2008	2
2009	9
2010	10
2011	6
2012	3
2013	3
2014	16
2015	9
2016	5
2017	7
2018	17
2019	7
2020	5
2021	6
2022	1

1

Meeting Report: 2013 PDA Virus & TSE Safety Forum.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Hubbard BR, Kreil TR, Ruffing M, Ruiz S, Scott D, Silvester G. Willkommen H, et al. PDA J Pharm Sci Technol. 2014 May-Jun;68(3):193-214. doi: 10.5731/pdajpst.2014.00980. PDA J Pharm Sci Technol. 2014. PMID: 25188343

2

Meeting Report: 2015 PDA Virus & TSE Safety Forum.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Kreil TR, Ruffing M, Ruiz S, Scott D, Silvester G. Willkommen H, et al. PDA J Pharm Sci Technol. 2016 Mar-Apr;70(2):177-88. doi: 10.5731/pdajpst.2016.006569. Epub 2016 Mar 28. PDA J Pharm Sci Technol. 2016. PMID: 27020643

3

Meeting Report: PDA Virus and TSE Safety Forum.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Kreil TR, Robertson JS, Ruffing M, Ruiz S. Willkommen H, et al. PDA J Pharm Sci Technol. 2013 Mar-Apr;67(2):81-97. doi: 10.5731/pdajpst.2013.00906. PDA J Pharm Sci Technol. 2013. PMID: 23569070 Review.

4

Meeting report-workshop on spike characterizations and virus removal by filtration: trends and new developments.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Hubbard BR, Kreil TR, Ruffing M, Ruiz S, Scott D, Silvester G. Willkommen H, et al. PDA J Pharm Sci Technol. 2014 May-Jun;68(3):215-20. doi: 10.5731/pdajpst.2014.00981. PDA J Pharm Sci Technol. 2014. PMID: 25188344

5

Meeting report--workshop on virus removal by filtration: trends and new developments.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Kreil TR, Robertson JS, Ruffing M, Ruiz S. Willkommen H, et al. PDA J Pharm Sci Technol. 2013 Mar-Apr;67(2):98-104. doi: 10.5731/pdajpst.2013.00907. PDA J Pharm Sci Technol. 2013. PMID: 23569071

6

Summary of the advanced virus detection technologies users group efforts-2013.

Duncan P. Duncan P. PDA J Pharm Sci Technol. 2014 Nov-Dec;68(6):548-51. doi: 10.5731/pdajpst.2014.01018. PDA J Pharm Sci Technol. 2014. PMID: 25475627

7

Use of substances of animal origin in pharmaceutics and compliance with the TSE-risk guideline -- a market survey.

Berger CN, Le Donne P, Windemann H. Berger CN, et al. Biologicals. 2005 Mar;33(1):1-7. doi: 10.1016/j.biologicals.2004.10.002. Biologicals. 2005. PMID: 15713551

8

Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.

Kozak RW, Golker CF, Stadler P. Kozak RW, et al. Dev Biol Stand. 1996;88:257-64. Dev Biol Stand. 1996. PMID: 9119148

9

Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.

Gefroh E, Dehghani H, McClure M, Connell-Crowley L, Vedantham G. Gefroh E, et al. PDA J Pharm Sci Technol. 2014 May-Jun;68(3):297-311. doi: 10.5731/pdajpst.2014.00978. PDA J Pharm Sci Technol. 2014. PMID: 25188350 Review.

10

The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.

Farshid M, Taffs RE, Scott D, Asher DM, Brorson K. Farshid M, et al. Curr Opin Biotechnol. 2005 Oct;16(5):561-7. doi: 10.1016/j.copbio.2005.07.006. Curr Opin Biotechnol. 2005. PMID: 16095899 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed